Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Methods of Cancer Diagnosis, Therapy and Prognosis
The enormity of the global healthcare costs vical. One-fifth of all cancers worldwide as a result of cancer infliction cannot be are caused by a chronic infection, for overemphasized. There are more than 100 example, human papilloma virus (HPV) types of cancers; any part of the body can causes cervical cancer and hepatitis B be affected. More than 11 million people virus (HBV) causes liver cancer. Tobacco are diagnosed with cancer every year, and use is the most common preventable cause it is estimated that there will be 16 mil- of cancer in the world. Approximately, lion new cases per year by the year 2020. 168,000 cancer deaths are expected to be In 2005, 7. 6 million people died of can- c...
Towards New Promising Discoveries for Lung Cancer Patients: A Selection of Papers from the First Joint Meeting on Lung Cancer of the FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (Houston, TX, USA)
This Special Issue of Cancers (Basel) is mainly dedicated to selecting papers from the talks given during the first Joint Meeting on Lung Cancer (JMLC) between the MD Anderson Cancer Center (Houston, Texas USA) and the Hospital University Federation (HUF) OncoAge (University Côte d’Azur, Nice, France) (Nice, September 2018). The central theme of JMLC is to discuss new advances and exchange ideas regarding lung cancer. Notably, the talks covered different topics on new therapeutic strategies (targeted therapy and immuno-oncology), molecular and cellular biology, biomarkers, and the epidemiology of lung cancer. Special attention was also given to lung cancer in elderly patients. The articles published in this Special Issue covered subjects such as the assessment of new biomarkers and new approaches for the early detection of lung cancer, epidemiological data, and emphasized a place for the newly characterized cellular pathways in lung cancer, which opens room for therapeutic perspectives for lung cancer patients.
Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs
Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a minor part of lung cancer patients harbouring specific mutations. In the so called wild type population, the first line options bring the median overall survival to go beyond 1 year, and in the population receiving the maintenance therapy over 16 months. Given these results, more than 60% of patients may receive a second line therapy with further opportunities to im...
Assessment and Treatment of Sarcopenia and Frailty in the Setting of Personalized Internal Medicine
The recognition and implementation of personalized internal medicine is of the utmost importance for physicians, nurses, dieticians and other healthcare professionals engaged in clinics. The assessment of sarcopenia and frailty, in middle-aged patients, as an embodiment of treatment personalization, is essential in settings of acute and chronic disease, both in the hospital and in ambulatory settings. This book describes various practical tools for the assessment of sarcopenia and frailty, reviews relevant findings from the current professional literature, and suggests treatment modifications for frail patients.
The Newcom++ Vision Book
The Book contains the Vision of the researchers of the European Network of Excellence NEWCOM++ (Network of Excellence on Wireless COMmunication) on the present and future status of Wireless Communication Networks. In its content, the community of NEWCOM++ researchers, shaped under the common ground of a mainly academic network of excellence, have distilled their scientific wisdom in a number of areas characterized by the common denominator of wireless communications, by identifying the medium-long term research tendencies/problems, describing the tools to face them and providing a relatively large number of references for the interested reader. The identified areas and the researchers involv...
Current Management Guidelines in Thoracic Surgery, An Issue of Thoracic Surgery Clinics
This issue highlights management issues surrounding specific subjects within the clinical practice of thoracic surgery. The articles represent areas of thoracic surgery where there may be controversy, lack of consensus, or evolution. Each author summarizes the available literature with the addition of his or her own personal expertise.
Breast Cancer in the Post-Genomic Era
Breast Cancer is the most common tumor in women and the second leading cause of cancer deaths worldwide. Due to breakthroughs in gene profiling, the knowledge of the pathophysiology of the mammary gland had greatly increased over the last decade. In Breast Cancer in the Post Genomic Era, Antonio Giordano, Nicola Normanno, and a panel of international authorities in their field provide a comprehensive approach to the biology, diagnosis, prevention, and treatment of human breast carcinoma. The book provides a comprehensive approach to breast cancer, describing the use of gene profiling techniques to distinguish specific features of individual carcinomas, as well as emerging novel therapeutic approaches to treatment. Additional chapters cover the use of transgenic mice to model human breast cancer and the role of the EGF-CFC family in mammary gland development and neoplasia. Breast Cancer in the Post Genomic-Era succeeds in looking at breast cancer pathogenesis, diagnosis, and treatment under a more comprehensive light, and is a valuable resource for any Radiation or Surgical Oncologist, Cancer Biologist or Pathologist.
COX-2 Inhibitor Research
COX-2 Inhibitors are newly developed drugs for inflammation that selectively block the COX-2 enzyme. Blocking this enzyme impedes the production of the chemical messengers (prostaglandins) that cause the pain and swelling of arthritis inflammation. Cox-2 inhibitors are a new class of nonsteroidal anti-inflammatory drugs (NSAIDS). Because they selectively block the Cox-2 enzyme and not the Cox-1 enzyme, these drugs are uniquely different from traditional NSAIDS. This book explores new research in this field.
Primary and Acquired Resistance in Lung Cancer
Lung cancer is one of the leading causes of cancer-related death worldwide with a prevalence of advanced stage in up to 70% of cases and a five-year survival reached in only 5-10% of cases. Targeted therapies and immunotherapy have greatly improved the management of patients with advanced non-small cell lung cancer (NSCLC), particularly adenocarcinoma, and current diagnostic algorithms are based on the molecular analysis of several biomarkers necessary to tailor therapy. In detail, patients harboring sensitive driver alterations within the oncogenes EGFR, BRAF, ALK, ROS1, RET and NTRK1/2/3 can be treated with approved kinase inhibitors (KIs). In addition, drugs against MET, KRAS G12C and other markers are providing interesting results across different clinical trials. Targeted therapies have greatly improved therapeutic options for NSCLC, but resistance inevitably occurs usually after one year of treatment and some patients, although harboring sensitive alterations, never respond to treatment.
